Re: RESVERLOGIX ANNOUNCES PUBLICATION OF KEY APABETALONE STUDY BETONMACE IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
posted on
Mar 31, 2020 08:00PM
RVX share price at 91 cents is down 26% YTD. That this is happening despite 1 BTD and a potential partnership deal (or buyout) speaks volumes of what the market thinks of RVX.
On the charts, there is no support left for RVX's share price. Next level is at 35 cents, the lows of last year. In other words, there are no buyers left; only sellers on any rally. RVX has zero credibility left with the markets. Markets are thinking of RVX as a ever running science experiment. It is high time they sold RVX to ANY bidder.